New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Where the cash went Q3 FY2026, quarter to Sep 30, 2026
Free cash flow was −$11.3M: capital expenditures were more than operating cash flow. Cash rose by $136.5M. What is a cash flow statement?
- Free cash flow
- −$11.3M
- Returned to shareholders
- $0.00
- Debt, net
- $0.00 borrowed
- Change in cash
- +$136.5M over the period
| Operating cash flow | −11.3 |
|---|---|
| Capital expenditures | 0.0 |
| Free cash flow | −11.3 |
| From investments, net | +5.2 |
| Shares issued, net | +140.5 |
| Other | +2.0 |
| Change in cash | 136.5 |
Figures in millions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Net Income |
+2 more quarters Free account |
11.86 | — | — | (9.86) |
Depreciation & Amortization |
— | — | — | 0.77 | |
Non Cash Items (Other) |
— | — | — | 1.26 | |
Accounts Receivable Change |
— | — | — | 0.23 | |
Accounts Payable Change |
— | — | — | 0.37 | |
Change in payables and accrued liability |
— | — | — | (0.33) | |
Change in other assets and liabilities |
— | — | — | (3.69) | |
Operating Cash Flow |
— | — | — | (11.25) | |
Capital expenditures |
— | — | — | (0.01) | |
Long-Term Investments Change (Net) |
— | — | — | 5.20 | |
Investing cash flow |
— | — | — | 5.18 | |
Equity Repurchase (Common, Net) |
— | — | — | 140.51 | |
Financing cash flow |
— | — | — | 142.53 | |
Change in Cash |
— | — | — | 136.46 | |
Beginning Cash |
— | — | — | 0.00 | |
Ending Cash |
— | — | — | 136.46 | |
Stock Based Compensation |
— | — | — | 1.22 | |
Dividends Paid (Common) |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Cash/Marketcap |
— | 0.00 | 0.00 | 0.00 | |
Assets Liabilities Change (Total) |
— | — | — | (3.42) | |
Investments Change (Net) |
— | — | — | 5.20 | |
Issuance/Purchase of Shares |
— | — | — | 140.51 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026